araag2/HINT huggingface dataset:
Clinical trial NCT01985724 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel, epirubicin, cyclophosphamide, 5-fluoruracil, granulocyte-colony stimulating growth factor
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, ClCCN(CCCl)P1(=O)NCCCO1, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Women with histologically-confirmed unilateral invasive ductal or lobular breast
             adenocarcinoma

          -  Within 60 days after the surgical excision of the primary tumor with tumor-free
             operation margins; at least 10 axillary lymph nodes have to be removed.

          -  Tumor involvement of at least one axillary lymph node

          -  Absence of any clinical or radiological evidence of local or metastatic disease

          -  Premenopausal or postmenopausal women aged 18-75 years old

          -  Adequate bone marrow function (absolute neutrophil count >1500/mm3, platelet count
             >100.000/mm3, hemoglobin >10gr/mm3)

          -  Adequate liver (bilirubin <1.0 times upper limit of normal and SGOT/SGPT <2.5 times
             upper limit of normal) and renal function (creatinine <1.5mg/dl)

          -  Adequate cardiac function (LVEF>50%)

          -  Written informed consent

        Exclusion Criteria:

          -  Positive pregnancy test.

          -  Psychiatric illness or social situation that would preclude study compliance.

          -  Other concurrent uncontrolled illness.

          -  Prior or concurrent antineoplastic therapy e.g. hormonal therapy, radiation therapy,
             chemotherapy, biological agents.

          -  Previous history of other invasive malignancy other than non-melanomatous skin cancer.
Clinical trial NCT01097616 (phase 3, status: completed)
Conditions: primary insomnia
ICD codes: F51.01
Drugs: suvorexant high dose (hd), suvorexant low dose (ld), comparator: placebo
SMILES: [H][C@@]1(C)CCN(CCN1C(=O)C1=C(C=CC(C)=C1)N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2, [H][C@@]1(C)CCN(CCN1C(=O)C1=C(C=CC(C)=C1)N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Must be ≥18 yrs old on the day of signing informed consent

          -  Diagnosed with Primary Insomnia

          -  Good physical and mental health

          -  Participant ≥65 yrs old score at least 25 on the Mini Mental State Examination

          -  A female participant who is of reproductive potential has a negative serum pregnancy
             test and agrees to use contraception

          -  Reports difficulty with initiating and maintaining sleep during the 4 weeks prior to
             Visit 1 (accordingly to specific protocol criteria)

          -  Reports spending 6.5 to 9 hours nightly in bed on at least 3 out of 7 nights prior to
             Visit 1

          -  Regular bedtime is between 9 pm-1 am

          -  Willing to refrain from napping while in study

          -  Able to read, understand and complete questionnaires and all diaries

          -  Willing to limit alcohol, caffeine, and nicotine consumption while in the study

          -  For a portion of participants: Must be willing to stay overnight in a sleep laboratory
             and must be willing to stay in bed for at least 8 hours each night while at the sleep
             laboratory

        Exclusion Criteria:

          -  Female participant is pregnant and/or breastfeeding at Prestudy visit, or expecting to
             conceive while in study

          -  History or diagnosis of another sleep disorder

          -  Difficulty sleeping due to a medical condition

          -  History of a neurological disorder

          -  History of bipolar disorder, psychotic disorder, or posttraumatic stress disorder, or
             current psychiatric disorder that requires a prohibited medication

          -  Ongoing depression

          -  History of substance abuse or dependence

          -  History or current evidence of a clinically significant cardiovascular disorder or
             clinically significant electrocardiogram (ECG) at Prestudy Visit

          -  Taking certain prohibited medications

          -  Consumption of the equivalent of >15 cigarettes a day

          -  History of malignancy ≤5 years prior to signing informed consent, except for
             adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer

          -  Participant is considered morbidly obese

          -  Previously randomized in another investigational study of suvorexant
Clinical trial NCT00615459 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: indacaterol, tiotropium, placebo
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female adults aged ≥ 40 years, who have signed an Informed Consent Form prior
             to initiation of any study-related procedure

          -  Co-operative out patients with a diagnosis of chronic obstructive pulmonary disease
             (COPD) (moderate to severe as classified by the Global initiative for chronic
             obstructive lung disease (GOLD) Guidelines, 2006) and:

               1. Smoking history of at least 10 pack years (current or previous smokers)

               2. Post-bronchodilator forced expiratory volume in 1 second (FEV1) < 80% and ≥30% of
                  the predicted normal value.

               3. Post-bronchodilator FEV1/Forced vital capacity (FVC) < 70%

        Exclusion Criteria:

          -  Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to
             Visit 1 or during the run-in period

          -  Patients requiring long-term oxygen therapy for chronic hypoxemia

          -  Patients who have had a respiratory tract infection within 6 weeks prior to Visit

          -  Patients with concomitant pulmonary disease

          -  Patients with a history of asthma

          -  Patients with diabetes Type I or uncontrolled diabetes Type II

          -  Any patient with lung cancer or a history of lung cancer

          -  Any patient with active cancer or a history of cancer with less than 5 years disease
             free survival time

          -  Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured
             at Visit 1 or randomization is prolonged

          -  Patients who have been vaccinated with live attenuated vaccines within 30 days prior
             to screening or during the run-in period.

          -  Patients unable to successfully use a dry powder inhaler device, MDI or perform
             spirometry measurements

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00399698 (phase 3, status: completed)
Conditions: oppositional defiant disorder, conduct disorder, attention deficit/hyperactivity disorder (adhd), intermittent explosive disorder, impulse-control disorders, adjustment disorder, bipolar disorder, pervasive developmental disorder
ICD codes: F91.3, F63.81, F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: risperdal
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Aged 4 to 14 years, inclusive

          -  Male or female gender

          -  Reason for receiving risperidone must include severe conduct problems

          -  Received risperidone treatment for at least 4 months

          -  Dosage in the range of 0.01 to 0.099 mg/kg/day

          -  Capable of discontinuing risperidone for up to 14 days in the judgement of child's
             physician

          -  Taking co-therapy with psychostimulants, antihistamines, melatonin, and chloral
             hydrate is allowed as long as co-therapy is held constant

          -  Taking co-therapy for sleep with guanfacine hydrochloride, clonidine hydrochloride,
             and trazodone hydrochloride is allowed so long as co-therapy is held constant

          -  Must have a reliable adult carer who can report on subject's behavior and attend
             scheduled assessments

          -  Parent or guardian must give informed consent, and subject must give assent if 14
             years of age or older

          -  Must be considered physically healthy on the basis of physical exam and medical
             history.

        Exclusion Criteria:

          -  Patients who meet DSM-IV criteria for schizophrenia, schizophreniform disorder,
             dissociative disorder, major depression, schizoaffective disorder, substance induced
             psychotic disorder

          -  Subjects who are pregnant

          -  Subjects with known seizure disorder

          -  Subjects with a history of neuroleptic malignant syndrome

          -  Subjects with a known or suspected history of severe drug allergy or hypersensitivity

          -  Subjects must have no significant medical disease

          -  Subjects must not be taking any other psychotropic medications.
Clinical trial NCT01007149 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: omalizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Severe persistent asthma with the following characteristics:

          -  Uncontrolled according to Global Initiative for Asthma (GINA) 2007 guidelines and at
             least 2 exacerbations having required systemic corticosteroid and/or at least 1
             hospitalization or emergency room visit in the past year.

          -  Treated with high-dose inhaled corticosteroid (i.e. > 1,000 µg beclometasone
             dipropionate equivalent per day) plus inhaled long-acting β2 agonist (with or without
             maintenance oral corticosteroid).

          -  Non-atopic, i.e. negative blood multiallergic testing and negative
             Aspergillus-specific IgE-radio allergosorbent blood test and negative skin prick tests
             to a battery of common aeroallergens

        Exclusion Criteria:

          -  Current smokers or smoking history stopped for less than 3 years or > 10 pack years.

          -  Asthma exacerbation during the 4 weeks prior to randomization.

          -  Active lung disease other than non-atopic asthma.

          -  Patients with an active cancer, a suspicion of cancer or any history of cancer with
             less than 5 disease free years.

          -  Pregnant or nursing (lactating) women.

          -  Treatment with omalizumab.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01333592 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: kad-1229
SMILES: [H][C@@](CC(=O)N1C[C@@]2([H])CCCC[C@@]2([H])C1)(CC1=CC=CC=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide
             or DPP-4 inhibitor monotherapy

          -  Age in the 20 years or over inclusive

          -  HbA1c in the range of ≥ 6.5 to < 9%

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Patients with serious diabetic complications and other serious complications
Clinical trial NCT00467376 (phase 3, status: completed)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: insulin glulisine, lispro, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 or type 2 diabetic patients

          -  Measure HbA1c 6.5% to 11.0% at visit 1

          -  More than 3 months of continuous insulin treatment immediately prior to study entry

        Exclusion Criteria:

          -  Pregnant women

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00549549 (phase 3, status: completed)
Conditions: arthritis, gouty
ICD codes: A01.04, A02.23, A39.83, A39.84, A54.42, B06.82, B26.85
Drugs: indomethacin, celecoxib, celecoxib, celecoxib
SMILES: COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Acute gouty arthritis meeting the American College of Rheumatology (ACR) criteria for
             acute arthritis of primary gout;

          -  Onset of pain from an acute gouty arthritis attack within 48 hours prior to
             Screening/Baseline (Visit 1);

          -  A rating of moderate, severe, or extreme (2, 3, or 4, respectively) on the Patient's
             assessment of pain intensity in the index joint (5-point scale:0-4) at
             Screening/Baseline.

        Exclusion Criteria:

          -  Diagnosis of any other type of arthritis including those types suspected of being
             infectious in origin in the index joint or presence of any acute trauma of the index
             joint. Patients with osteoarthritis will be included as long as it is mild or moderate
             (according to investigator's criteria) and it does not affect the index joint;

          -  Acute polyarticular gout involving greater than 4 joints or chronic gout.
Clinical trial NCT00257972 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: aripiprazole
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of bipolar I disorder, manic or mixed episode

        Exclusion Criteria:

          -  First manic or mixed episode

          -  Allergic, intolerant, or unresponsive to lithium and valproate or to aripiprazole

          -  Participation in a previous clinical trial within the past month or ever participated
             in a trial with aripiprazole
Clinical trial NCT00003592 (phase 3, status: completed)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: methotrexate, paclitaxel
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed advanced, incurable, squamous cell
        carcinoma of the head and neck Recurrent disease in a previously irradiated field must be
        biopsy proven or documented unequivocally by physical exam or radiograph(s) Measurable or
        evaluable disease Patients with ECOG performance status of 0-1 must be ineligible for
        protocol E-1395 and unable to tolerate cisplatin-based therapy for 1 or more of the
        following reasons: Hearing loss that precludes cisplatin Unable to handle a fluid load
        necessitated by cisplatin-based treatment, due to underlying cardiac or pulmonary disease
        Mild renal insufficiency (creatinine 1.6-2.0 mg/dL) or creatinine clearance of 40-60 mL/min
        that would make cisplatin treatment difficult, if not dangerous History of brain metastases
        allowed if disease has stabilized or improved after radiation and/or craniotomy No history
        of carcinomatous meningitis

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 (See Disease
        Characteristics) Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at
        least 1,800/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5
        mg/dL SGOT and SGPT no greater than 5 times upper limit of normal Renal: See Disease
        Characteristics Creatinine no greater than 2.0 mg/dL No evidence of symptomatic
        hypercalcemia Cardiovascular: See Disease Characteristics No active angina or uncontrolled
        arrhythmias Metabolic: No uncontrolled diabetes; no random blood sugar at least 300 mg/dL
        Neurological: No evidence of ongoing grade 2 or greater peripheral sensory neuropathy
        Pulmonary: See Disease Characteristics Other: No other concurrent, active, invasive
        malignancies No significant detectable infection Not pregnant or nursing Effective
        contraception required of all fertile patients

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy except in the adjuvant, neoadjuvant, or radiosensitizing setting No prior
        chemotherapy for recurrent or persistent disease after definitive local therapy At least 6
        months since prior methotrexate or paclitaxel Endocrine therapy: Not specified
        Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy
        Surgery: See Disease Characteristics Recovered from prior surgery
Clinical trial NCT00314171 (phase 3, status: completed)
Conditions: open-angle glaucoma, ocular hypertension
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131, H40.053, H40.051, H40.052, H40.059
Drugs: brinzolamide 10 mg/ml + timolol 5 mg/ml eye drops, suspension, dorzolamide 20 mg/ml + timolol 5 mg/ml eye drops, solution (cosopt)
SMILES: [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 years or older

          -  Diagnosis of open-angle glaucoma or ocular hypertension

          -  Other protocol-defined inclusion criteria may apply

        Exclusion Criteria:

          -  Under 18

          -  Pregnant

          -  Other protocol-defined exclusion criteria may apply
Clinical trial NCT01209702 (phase 3, status: terminated)
Conditions: spondylitis, ankylosing
ICD codes: M08.1, M45.6, M45.2, M45.3, M45.4, M45.5, M45.7
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    recruitment halted: failed to achieve efficacy
  
Eligibility criteria:

        Inclusion Criteria

          -  Adult patients, ≥ 18 years of age

          -  Ankylosing Spondylitis as defined by the modified New York criteria for ≥ 3 months
             prior to baseline

          -  Active disease at screening and baseline (Bath Ankylosing Spondylitis Disease Activity
             Index [BASDAI] ≥4.0, spinal pain visual analog scale [VAS] ≥40)

          -  Inadequate response or intolerant to 1 or more previous non-steroidal
             anti-inflammatory drugs (NSAIDs)

          -  Traditional disease-modifying anti-rheumatic drugs (DMARDs) must be withdrawn for at
             least 4 weeks prior to baseline (methotrexate, sulfasalazine and hydroxychloroquine or
             chloroquine may be allowed if at stable dose for at least 4 weeks prior to baseline)

          -  Oral corticosteroids (≥ 10 mg/day prednisone or equivalent) and NSAIDs/COX-2
             inhibitors must be at stable dose for at least 4 weeks prior to baseline

        Exclusion Criteria:

          -  Major surgery (including joint surgery) within 8 weeks prior to screening or planned
             major surgery within 6 months after randomization

          -  Total ankylosis of spine (as determined by investigator)

          -  Inflammatory rheumatic disease other than ankylosing spondylitis

          -  Active, acute uveitis at baseline

          -  Treatment with tumor necrosis factor (TNF) antagonist therapy at any time prior to
             baseline

          -  Intra-articular or tendon injections or parenteral corticosteroids within 4 weeks
             prior to screening

          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
             antibodies

          -  Active current or history of recurrent bacterial, viral, fungal, mycobacterial or
             other infection

          -  History of or currently active primary or secondary immunodeficiency

          -  Body weight > 150 kg
Clinical trial NCT00146016 (phase 3, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: amantadine
SMILES: NC12CC3CC(CC(C3)C1)C2
Eligibility criteria:

        Inclusion Criteria:

          -  Anti-HCV positivity >6 months

          -  ALT and/or AST elevation on at least once in the previous 6 months

          -  Positive HCV-RNA

          -  Liver biopsy within one year before the start of therapy in non- cirrhosis. In the
             case of known cirrhosis, liver biopsy is not necessary

          -  Intention to be treated and participate treatment

          -  Obtained written informed consent

        Exclusion Criteria:

          -  Age < 18 years

          -  Pregnancy or intention to get pregnant within the 12 months period of treatment and up
             to 6 months after discontinuation of therapy, no adequate contraception, lactation

          -  Men not practicing or willing to practice acceptable methods of contraception during
             the treatment period and up to 6 months after discontinuation of therapy

          -  Life expectancy < 1 year

          -  Child Pugh B or C (Appendix III)

          -  Creatinine > 150 μmol/L or > 1.70 mg/dl

          -  Haemoglobulin < 6.5 mmol/l or < 10.5 g/dl

          -  White blood cell count < 2,5 x 109/L, neutrophil < 1,5 x 109/L

          -  Platelet count < 70 x 109/L

          -  HIV positivity

          -  Chemotherapy, systematical antiviral treatment during the 6 months prior to study
             entry

          -  Other serious disease (e.g. malignancy, uncontrolled myocardial disease or severe
             arrhythmias)

          -  Active uncontrolled psychiatric disorders and suicidal leanings

          -  Patients with a history of uncontrolled seizure or other significant CNS dysfunction

          -  Any condition which in the opinion of the (co-)investigator might interfere with the
             evaluation of the study objectives
Clinical trial NCT01516814 (phase 3, status: completed)
Conditions: pulmonary embolism
ICD codes: I27.82, Z86.711, I26.01, I26.09, I26.90, I26.99, I26.93
Drugs: rivaroxaban (xarelto, bay59-7939), unfractionated heparin, warfarin
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O, S1SSSSSSS1
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women >/= 20 years of age in patients with confirmed acute symptomatic
             pulmonary embolism (PE) with or without symptomatic deep vein thrombosis (DVT)

        Exclusion Criteria:

          -  Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the
             current episode of PE

          -  More than 48 hours pre-randomization treatment with therapeutic dosages of
             anti-coagulant treatment or more than a single dose of warfarin from the onset of the
             current episode of PE to randomization

          -  Calculated creatinine clearance (CLCR) < 30 mL/min

          -  Subjects with hepatic disease which is associated with coagulopathy leading to a
             clinically relevant bleeding risk

          -  Active bleeding or high risk for bleeding contraindicating treatment with unfractioned
             Heparin (UFH) or warfarin

          -  Systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg